News and Resources

November 20, 2024

Nature Publication Supports Senolytic Approach for Cancer Treatment

November 3, 2024

Immorta CSO Featured in BioFuture 2024 Longevity Panel

October 29, 2024

Immorta Bio's SenoVax™ Reduces Growth and Stops Metastasis of Aggressive Breast Cancer Using its First-In-Class Immune Stimulatory Therapy

October 21, 2024

Featured on The Bio Report Podcast - Targeting Senescent Cells

October 17, 2024

Immorta Bio CEO Featured in Empowered Patient Podcast

October 16, 2024

Immorta Bio - Featured on Pharmaceutical Executive

October 2, 2024

Diseases of Aging: Q&A with Dr. Thomas Ichim

September 5, 2024

SenoVax™ Breakthrough: Cancer Immunotherapy Preserves Immune Function Post-Chemotherapy in Animal Models

August 13, 2024

Immunotherapy Success Reinforces Immorta's Innovative Cancer Treatment Strategy

July 30, 2024

Dr. Russel Kaufman, Renowned Medical Innovator and Business Leader, Joins Immorta Bio's Board of Directors

July 26, 2024

Immorta Bio Files Investigational New Drug Application for First in Class Senolytic Immunotherapy SenoVax™ for Treatment of Advanced Lung Cancer

June 12, 2024

Senovax™: cutting-edge immunotherapy for lung cancer

June 12, 2024

Immorta Bio Reports Successful Inhibition of Lung Cancer Growth by Senolytic Immunotherapy Product SenoVax™

May 24, 2024

Pmsc-11: pioneering liver failure treatment with stem cells

May 23, 2024

Immorta Bio Inc, a Longevity Company, Announces a Significant Breakthrough in Treatment of Liver Failure

May 7, 2024

Muscle revival: mitochondrial transplants for aging

April 23, 2024

Young mice plasma sevs: unlocking the secret to longevity

April 9, 2024

Telomir-1: the next breakthrough in anti-aging therapy

March 26, 2024

Surprising longevity boosters: top medications revealed

March 12, 2024

Patent spotlight: zip11 gene and the future of anti-aging therapies

Join our newsletter to stay up to date on features and releases
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By subscribing, you are acknowledging your consent to receive  Immorta Bio newsletters
19505 Biscayne Blvd, Ste 2350 Aventura, Florida 33180
305 632-2939
info@immortabio.com